Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BGQOD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Olintatug tesirine
|
|||||
| Synonyms |
olintatug tesirine; 3A4-PL1601; ADCT-901
Click to Show/Hide
|
|||||
| Organization |
ADC Therapeutics (Originator);MedImmune (Top20 MNC);Overland Pharmaceuticals
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Structure |
|
|||||
| Antibody Name |
Olintatug
|
Antibody Info | ||||
| Antigen Name |
Kidney-associated antigen 1 (KAAG1)
|
Antigen Info | ||||
| Payload Name |
SG3199 (SC-DR002)
|
Payload Info | ||||
| Payload Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mal-PEG8-Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
tesirine
|
|||||
2027 Update
The indication landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Biliary tract cancer |
1 Trials
|
|||||
| Breast cancer |
1 Trials
|
|||||
| Ovarian cancer |
1 Trials
|
|||||
| Fallopian tube cancer |
1 Trials
|
|||||
| Prostate cancer |
1 Trials
|
|||||
| Kidney cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants had advanced/metastatic solid tumors (cholangiocarcinoma, ovarian/prostate/RCC/TNBC), measurable disease per RECIST v1.1 (prostate cancer allowed with bone metastases + PSA ≥2 ng/mL). Exclusions included active infections, symptomatic CNS metastases (unless treated/asymptomatic for ≥4 weeks), clinically significant effusions, CTCAE Grade 2+ diarrhea, ocular surface disease (except managed mild dry eye), and recent experimental drug use (14-day washout).
Click to Show/Hide
|
||||
| Administration Dosage |
Part 1: pts will receive escalating doses of ADCT-901 guided by a 3+3 design (1st dose: 15 ug/kg every 3 weeks [Q3W]; highest dose: 290 ug/kg Q3W). Dose escalation will be evaluated by administering the lowest dose to first 3 pts, then increasing/decreasing the dose based on dose-limiting toxicity (DLT) experienced by pts.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04972981 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors | ||||
| Primary Endpoint |
Safety was evaluated by AE/SAE incidence (including clinical lab/ECG changes) over 2.5 years, with DLTs tracked during dose escalation (Days 1-21), alongside dose modifications (interruptions/reductions).
|
||||
| Other Endpoint |
Efficacy endpoints (ORR, DOR, PFS, OS) and comprehensive PK parameters (Cmax, Tmax, AUC metrics, half-life, clearance, ADA response) for ADCT-901 components (total antibody, PBD-conjugated antibody, SG3199) were monitored throughout the 2.5-year study period.
|
||||
References